Moderna shares plunge after leak of partial cancer vaccine data

Moderna shares fell as much as 25% Thursday after partial data leaked on its cancer vaccine developed with Merck. Full late-stage trial data released later appeared positive against Wall Street expectations: intismeran autogene plus Keytruda reduced recurrence-or-death risk by 42% versus Keytruda alone in certain melanoma patients. The results are due to be presented at the European Society for Medical Oncology conference this weekend.

Analysis

The selloff looks more like a positioning/liquidity event than a clean reassessment of the trial: leaked partial results can create uncertainty, while a sharp decline despite apparently favorable full data raises the bar for a durable rebound. That is not, by itself, evidence of mispricing. For MRNA, the investment case depends on whether the conference presentation confirms clinically meaningful absolute benefit, acceptable safety, and durability—not just a favorable relative-risk statistic. The result may validate Moderna’s personalized-oncology platform, but it does not establish scalable manufacturing, broad applicability beyond the studied melanoma population, or attractive economics; partnership terms and commercial contribution remain key unknowns.

MRK’s exposure is more incremental: a successful combination could reinforce Keytruda’s role in an additional regimen, but the data alone do not establish material revenue uplift or the economics shared with Moderna. Over the next few days, conference detail and management commentary should dominate; over 1–3 months, focus on analyst revisions and evidence of a sustained recovery in MRNA rather than assuming the initial drawdown reverses. Over 6–18 months, execution, regulatory path, and whether personalized vaccine production can scale are the structural tests. The contrarian opportunity is a potential overshoot in MRNA, but buying before those details are verified risks mistaking event-driven selling for a fundamental warning.

Key Decisions for Investors

• Do not chase either the selloff or an immediate bounce. Use the ESMO presentation as the next decision point; verify absolute recurrence outcomes, follow-up, overall-survival maturity, safety, and consistency across relevant subgroups.
• Watch MRNA for a staged, defined-risk long only if the full presentation corroborates the headline efficacy and the post-event price action stabilizes. The thesis is falsified by materially weaker absolute benefit, concerning safety, or management commentary that narrows the addressable population or delays development.
• Treat MRK as a watch rather than a direct read-through trade: confirm whether the combination has a credible path to incremental Keytruda use and clarify commercial economics before attributing meaningful value to the result.
• Track MRNA’s post-conference volume and relative performance versus biotech peers. Persistent underperformance after detailed data, or a subsequent trial/regulatory setback, would argue that the decline reflects more than a temporary leak-driven positioning unwind.